Retatrutide, a next-generation triple-target peptide API, simultaneously activates the GLP-1, GIP, and glucagon receptor (GCGR) pathways, making it a core active pharmaceutical ingredient for innovative metabolic therapeutics. Manufactured using a fully solid-phase peptide synthesis process, the product achieves a purity of ≥99.5%. Impurity profiles comply with ICH quality standards, while the peptide structure remains intact with stable and consistent biological activity.
Produced at stable kilogram-scale capacity in GMP-compliant manufacturing facilities, the product is supplied as a lyophilized powder for convenient storage and formulation. Complete documentation, including a Certificate of Analysis (COA) and comprehensive impurity profiling, is provided to support pharmaceutical formulation development and regulatory submissions. Through the synergistic activation of three metabolic pathways, Retatrutide delivers comprehensive glycemic control, appetite suppression, and enhanced fat oxidation, demonstrating superior clinical performance in weight reduction and glucose management compared with single- or dual-target peptide therapies.